Wir sind mit live! Mehr erfahren

Assembly Biosciences

ASMB

Börsenwert 409 Mio. $

20,09 USD

-0,48

2,33 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-2,33 %

5 Tage

-14,26 %

1 Monat

-21,15 %

3 Monate

-22,25 %

6 Monate

-31,48 %

Seit Jahresbeginn

-40,47 %

1 Jahr

-30,91 %

5 Jahre

-47,85 %

10 Jahre

-85,86 %

Profil: Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Mitarbeiter: 73

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 70 %

Neutral 30 %

Negativ 0 %

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

Zacks Investment Research

Best Momentum Stocks to Buy for September 17th

MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.

Best Momentum Stocks to Buy for September 17th

Zacks Investment Research

New Strong Buy Stocks for September 17th

MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.

New Strong Buy Stocks for September 17th

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

Zacks Investment Research

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Zacks Investment Research

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

Zacks Investment Research

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Zacks Investment Research

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.

5 Stocks With Recent Price Strength Buoyed by a Strong August

Zacks Investment Research

Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt